CTIM-30. EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH PITUITARY CARCINOMA: RESULTS FROM A PHASE II STUDY

Pituitary carcinoma is an aggressive tumor characterized by metastatic spread beyond the sellar region that leads to debilitating symptoms and poor survival. Pituitary carcinomas recur despite conventional multimodality treatments. Given the recent advances in the use of immune checkpoint inhibitors...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Neuro Oncol
Päätekijät: Majd, Nazanin, Waguespack, Steven, Filip, Janku, Fu, Siqing, Penas-Prado, Marta, Xu, Mingxuan, Alshawa, Anas, Kamiya-Matsuoka, Carlos, Raza, Shaan, McCutcheon, Ian, Aung, Naing
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Oxford University Press 2020
Aiheet:
Clinical Trials: Immunologic
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7650354/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.164
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia